基本信息
浏览量:12
职业迁徙
个人简介
Research Topics
Dr. Merke has made significant contributions to the study of CAH, including the novel finding of adrenaline deficiency in patients with CAH; the discovery that patients with CAH have smaller-than-normal amygdalas (the part of the brain that regulates emotion); and identification of problems with hydrocortisone suspension, a common medication used by patients with CAH. (Dr. Merke's studies led to a product recall). She currently is conducting the largest ever Natural History Study of CAH, with more than 250 patients enrolled in a study that aims to broaden our understanding of the disease process.
Dr. Merke leads an effort to expand our understanding of the pathophysiology and clinical manifestations of CAH. As part of this work, her group has explored genetic variability in relation to phenotype and has defined a novel connective tissue phenotype in a subset of CAH patients due to a contiguous gene deletion syndrome, termed here CAH-X Syndrome.
Central to her work is the study of new treatments, including a long-term trial testing an antiandrogen and aromatase inhibitor to block excess hormones, and the study of a newly developed form of hydrocortisone which mimics circadian cortisol secretion. She received grants (2005 to 2009) from the Congenital Adrenal Hyperplasia Research, Education and Support Foundation. She has published widely in New England Journal of Medicine, Lancet, Journal of the American Medical Association, the Journal of Clinical Endocrinology and Metabolism, and in other medical journals.
Dr. Merke has made significant contributions to the study of CAH, including the novel finding of adrenaline deficiency in patients with CAH; the discovery that patients with CAH have smaller-than-normal amygdalas (the part of the brain that regulates emotion); and identification of problems with hydrocortisone suspension, a common medication used by patients with CAH. (Dr. Merke's studies led to a product recall). She currently is conducting the largest ever Natural History Study of CAH, with more than 250 patients enrolled in a study that aims to broaden our understanding of the disease process.
Dr. Merke leads an effort to expand our understanding of the pathophysiology and clinical manifestations of CAH. As part of this work, her group has explored genetic variability in relation to phenotype and has defined a novel connective tissue phenotype in a subset of CAH patients due to a contiguous gene deletion syndrome, termed here CAH-X Syndrome.
Central to her work is the study of new treatments, including a long-term trial testing an antiandrogen and aromatase inhibitor to block excess hormones, and the study of a newly developed form of hydrocortisone which mimics circadian cortisol secretion. She received grants (2005 to 2009) from the Congenital Adrenal Hyperplasia Research, Education and Support Foundation. She has published widely in New England Journal of Medicine, Lancet, Journal of the American Medical Association, the Journal of Clinical Endocrinology and Metabolism, and in other medical journals.
研究兴趣
论文共 12 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
DEBORAH P. MERKE, JEREMY D. FIELDS,MARGARET F. KEIL,A. CATHERINE VAITUZIS,GEORGE P. CHROUSOS,JAY N. GIEDD
Richard J Auchus, Selma Wichel,Perrin C White,Linda A Baker, Arlene Baratz, Sheri A Berebaum,Erica A Eugster,Mitchell E Geffner,Karen J Loechner,Deborah Merke, Tamara Nenadovich,Dix P Poppas,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn